Sergio Abrignani, MD, PhD

T-One Therapeutics co-founder

INGM Scientific Director

Full professor in Pathology at UniMi

+39 0200660203

abrignani@tonetx.eu

Sergio Abrignani is Manager and Scientific Director of INGM, the Istituto Nazionale di Genetica Molecolare “Romeo ed Enrica Invernizzi”, and full professor of Pathology and Immunology at the University of Milan. He has 20 years of international experience in vaccine research in pharma and biotech environment and 15 years of academic research experience in a “no-profit” research Institute (INGM) at the University of Milan.

Sergio is M.D. from the University of Padova. From 1986 to 1993 he worked, as lab head, at the Research Centre of Ciba-Geigy in Basel (Switzerland). From 1993 to 1999 he was Director of the Immunology and Virology Research Unit at Chiron Vaccines in Siena (Italy).

From 1999 to 2005 he was Vice President of R&D at Chiron Corporation in San Francisco (USA). Since 2006 he is Manager and Scientific Director of INGM, a no-profit research foundation aimed at the discovery and initial development of new therapies and new diagnostics for human diseases (neoplastic, infectious and autoimmune) with particular interest into secondary prevention.

Sergio Abrignani’s research activity has focused on immunology and on the interactions between viruses and human cells. Sergio has published about 130 scientific papers with an h-index of 73 (GS), more than 22000 citations, and has about 30 granted international patents. He is member of many Italian and international scientific societies and academies. Because of his studies on the hepatitis C virus, in 2004 he received the Public Health gold Medal of Merit from the President of the Italian Republic.

In 2011 he was awarded an “Advanced Grant” of the European Research Council (ERC), the most important and prestigious competitive grant for European researchers. He has been a member of the “Consiglio Superiore di Sanità” of the Ministry of Health since 2019 and in 2021 he has been appointed member of the Italian National Advisory Board (CTS) for the COVID pandemic.